In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Ophthalmics AG

Division of Novartis AG
www.novartisophthalmics.com

Latest From Novartis Ophthalmics AG

Business & Technology Briefs (06/2007)

Brief summaries of recent product and company developments in the device industry, including Aspect Medical's brain monitoring technology, Warburg's bid for Bausch & Lomb, and Frazier Healthcare Venture's investment in publicly-traded Endocare.

A White Knight for Bausch & Lomb

Bausch & Lomb was slogging forward after a difficult year-the company had been embroiled in a lengthy accounting investigation involving some of its foreign subsidiaries since the end of 2005 and in early 2006 it was compelled to recall its most profitable product-. In mid-May 2007 Bausch & Lomb was wrestling with a 3% decrease in annual sales, 344 product liability lawsuits, and an overhanging intellectual property case that could affect its fastest growing contact lens line, when up galloped white knight private equity firm Warburg Pincus, with a $4.5 billion offer to take the ophthalmic company private.

Ophthalmology's Next Frontier

Millions of middle-aged and soon-to-be elderly people worldwide are running headlong into vision problems, and this looming patient pool is already beginning to steer the future course of physician practice and research and development dollars. The potential for huge rewards is certainly present for developers of safe, effective new therapies for disorders of the aging eye.
Medical Device Innovation

Othera Pharmaceuticals Inc.

Othera Pharmaceuticals Inc. is eyeing some big opportunities in ophthalmology. The specialty pharma's first targets include the billion-dollar cataract and glaucoma markets, as well as another large, undermet ocular disease: dry age-related macular degeneration. Othera has in-licensed a novel antioxidant that it believes has unique potential to address these and other conditions caused by free-radical induced oxidative damage.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ciba Vision Ophthalmics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Luzi von Bidder, Pres.
  • Contact Info
  • Novartis Ophthalmics AG
    Phone: (41)
    Hettlingen, 8442
    Switzerland
UsernamePublicRestriction

Register